The Focus-activity Framework for Evaluating PSS Cooperation Readiness of Manufacturing Firms

For manufacturing companies venturing the first steps on the Servitization roadmap, it may be difficult to imagine how an integrated approach of Product and Service elements could support the strategic goals efficiently. If Service tasks, roles, units and organizational structure are still developing and emerging from the Product business activities, the design of Product-Service cooperation as well is promising, as the way is unclear. For these companies, it seems to be important to understand their current status of Product-Service cooperation at first, before starting to design integration activities. Therefore, this paper presents a framework which is designed to help companies identify their current status – and strategic objectives later on – at two dimensions: a) the Structural Focus of Product and Service business within the company, and b) the Cooperation Activities which are undertaken by Product and Service representatives. By the means of a case study in the Italian luxury textile sector, a first validation of the model is conducted, assessing the static and dynamic characteristics of Product and Service business with involvement of an Italian textile company

LE REGOLE E LA VITA. DEL BUON USO DI UNA CRISI, TRA LETTERATURA E DIRITTO

Even from the dramatic crisis underway valuable experiences can and should be drawn, to make good use of them, for now and for tomorrow. Among such experiences the new and fundamental one, both for legal professionals and for ordinary citizens, is the vision of a world of rules on the observance or transgression of which people's lives are being played out. Rules that reveal in full view, as rarely happens, the language with which life, nature and the environment speak to us. From now on, the entire regulatory system should pay attention to this language. It is the conviction that inspires this book, born from the hope that the "Federico Stella" Postgraduate School on Criminal Justice had a 'way' to talk to the country and to the academic community about the huge problem of the pandemic that we are all facing together, to prepare ourselves with awareness and determination to the great challenges that we all will confront in the next months and years

Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group

Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an increasing role in the management of nodules causing local symptoms. In February 2018, the Italian MIT Thyroid Group was founded to create a permanent cooperation between Italian and international physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted this list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1) Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspiration = 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist after ethanol ablation (LoE = 4); (#3) Double cytological benignity confirmation is needed before thermal ablation (LoE = 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS 643) and in autonomously functioning nodules (LoE = 2); (#5) Thermal ablation may be proposed as first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE = 2); (#6) Thermal ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/not eligible for surgery (LoE = 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal ablation (LoE = 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially resolve (LoE = 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before second ablation (LoE = 5); (#10) Thermal ablation is an option for autonomously functioning nodules in patients refusing/not eligible for radioiodine or surgery (LoE = 2); (#11) Small autonomously functioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and 6580% nodule volume ablation is expected (LoE = 3)

Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review

Prostate cancer (PCa) is the second leading cause of cancer among men, and its diagnosis and adequate staging are fundamental. Among the biomarkers identified in recent years for PCa management, prostate-specific-membrane-antigen (PSMA), physiologically expressed at a low level on healthy prostate and in other normal tissues and highly overexpressed in PCa, represents a reliable marker ideal for imaging and therapy. The development of anti-PSMA antibodies, such as D2B, demonstrated slow clearance of intact antibodies compared with fragments resulting in low tumor-to-blood ratios; however, the modular structural and functional nature of antibodies allowed the generation of smaller fragments, such as scFvs. In this review of the anti-PSMA antibody fragment scFvD2B, we combined further characterization of its biomolecular and tissue cross-reactivity characteristics with a comprehensive summary of what has already been performed in preclinical models to evaluate imaging and therapeutic activities. A molecular dynamics study was performed, and ScFvD2B occupied a limited conformational space, characterized by low-energy conformational basins, confirming the high stability of the protein structure. In the cross-reactivity study, the weak/absent immunoreactivity in non-tumor tissues was comparable to the PSMA expression reported in the literature. Biodistribution studies and therapeutic treatments were conducted in different animal models obtained by subcutaneous or locoregional injection of PSMA-positive-versus-negative xenografts. The maximum tumor uptake was observed for (123)I(SPECT), (124)I(PET), and optical imaging, which avoids kidney accumulation (compared with radiometals) and leads to an optimal tumor-to-kidney and tumor-to-background ratios. Regarding its possible use in therapy, experimental data suggested a strong and specific antitumor activity, in vitro and in vivo, obtained using CAR-T or NK-92/CAR cells expressing scFvD2B. Based on presented/reviewed data, we consider that scFvD2B, due to its versatility and robustness, seems to: (i) overcome some problems observed in other studied scFvs, very often relatively unstable and prone to form aggregates; (ii) have sufficient tumor-to-background ratios for targeting and imaging PSMA-expressing cancer; (iii) significantly redirect immune killing cells to PSMA-positive tumors when inserted in second-generation CAR-T or NK-92/CAR cells. These data suggest that our product can be considered the right reagent to fill the gap that still exists in PCa diagnosis and treatment

Comparison of risk of acute kidney injury after primary percutaneous coronary interventions with the transradial approach versus the transfemoral approach (from the PRIPITENA urban registry)

The risk of acute kidney injury (AKI) is a major issue after percutaneous coronary interventions (PCIs), especially in the setting of ST-elevation myocardial infarction. Preliminary data from large retrospective registries seem to show a reduction of AKI when a transradial (TR) approach for PCI is adopted. Little is known about the relation between vascular access and AKI after emergent PCI. We here report the results of the Primary PCI from Tevere to Navigli (PRIPITENA), a retrospective database of primary PCI performed at high-volume centers in the urban areas of Rome and Milan. Primary end point of this study was the occurrence of AKI in the TR and transfemoral (TF) access site groups. Secondary end points were major adverse cardiovascular events, stent thrombosis, and Thrombolysis in Myocardial Infarction major and minor bleedings. The database included 1,330 patients, 836 treated with a TR and 494 with a TF approach. After a propensity-matched analysis performed to exclude possible confounders, we identified 450 matched patients (225 TR and 225 TF). The incidence of AKI in the 2 matched groups was lower in patients treated with TR primary PCI (8.4% vs 16.9%, p = 0.007). Major adverse cardiovascular events and stent thrombosis were not different among study groups, whereas major bleedings were more often seen in the TF group. At multivariate analysis, femoral access was an independent predictor of AKI (odds ratio 1.654, 95% confidence interval 1.084 to 2.524, p = 0.042). In conclusion, in this database of primary PCI, the risk of AKI was lower with a TR approach, and the TF approach was an independent predictor for the occurrence of this complication. © 2014 Elsevier Inc. All rights reserved

Conceptual Framework for Product Service Systems

To remain competitive in the current market, an enterprise must differentiate itself based on higher value propositions. For this purpose, since improving the product or service performance can reach some limits, one potential solution is to move towards new combinations of products and services. This evolution, called servitization, leads to the generation of Product Service Systems (PSS). Servitization requires not only a clear understanding of enterprise core business, but also a clear vision of the prevailing trends and challenges of PSS development from both the business and technological points of view. In addition, the evolution path should be aligned with the enterprise strategy. This paper first highlights the notion of symbiotic PSS where product systems and service systems, and their stakeholders, interoperate seamlessly based on a win-win approach. Then, it proposes a PSS Conceptual Framework (PSS-CF), which can be applied in the early stages of servitization to increase the understating of PSS dimensions and to facilitate the prioritization of the servitization investments. The framework dimensions were discussed in several iterations, from both the academic and industrial points of view, in the frame of a European research project. Moreover, the applicability of the framework was studied in four different industrial use-cases

Tra Giustizia e Letteratura. Un'avventura del pensiero

Ogni ordinamento giuridico, se vuole essere davvero a misura d’uomo, deve comprendere la natura intrinsecamente narrativa dell’umano, del nostro essere per vocazione narratori e ascoltatori di storie: solo attraverso questa riconciliazione con la mutevolezza dell’esistenza è possibile mantenere la stabilità e coerenza delle regole ma al contempo venire incontro pienamente alla richiesta di giustizia della società umana. È qui che nasce il bisogno di un dialogo sempre aperto tra diritto e letteratura, essenziale per tutti coloro che concorrono a vario titolo all’amministrazione della giustizia: magistrati, avvocati, ma anche semplici cittadini. Questo volume sintetizza la grande avventura scaturita da una tale consapevolezza e attraversata nell’arco di quasi quindici anni dall’Alta Scuola “Federico Stella” sulla Giustizia Penale con il progetto ‘Giustizia e letteratura’. Gli agili saggi di taglio divulgativo che lo compongono illustrano alcune delle opere e degli ambiti letterari esplorati nel corso di questo lungo cammino, da Manzoni a Sciascia, da Shakespeare a Steinbeck, dal grande canone letterario a qualificate opere di genere, con incursioni nel giallo e nella fantascienza. [Seconda di copertina

Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group

: Radioligand therapy (RLT) with lutetium (177Lu) oxodotreotide is an approved therapy in combination with somatostatin analogues (SSAs) for patients with advanced, well-differentiated G1-G2, gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs) that progress on SSAs. We conducted a series of round table meetings throughout Italy to identify issues related to RLT delivery to patients with GEP-NETs. Four key issues were identified: (1) the proper definition of tumour progression prior to RLT initiation; (2) the impact of RLT in patients with bone metastases and/or high hepatic tumour burden; (3) the optimal follow-up protocol after RLT; and (4) organisational issues related to RLT use and managerial implications. This article reviews the literature relating to the aforementioned issues and makes recommendations based on available evidence and Italian NET experts' opinions. In particular, the group recommends the development of a diagnostic-therapeutic care pathway (DTCP) for patients undergoing RLT which provides systematic guidance but can still be individualised for each patient's clinical and psychosocial needs. A DTCP may clarify the diagnostic, therapeutic and post-treatment monitoring process, and improve communication and the coordination of care between hub and spoke centres. The DTCP may also contribute to changes in the care process related to the 2013/59/EURATOM Directive and to the definition of costs when planning for future or updated reimbursement of RLT in Italy